Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for Priority Review the supplemental ...

Regeneron’s (REGN) odronextamab was granted FDA orphan designation as a treatment of splenic marginal zone lymphoma, according to a post to the ...

AZ and Regeneron will collaborate on finding small-molecule drugs directed against the GPR75 target, splitting the costs of the programme and sharing any resulting profits from the endeavour.